New Italian Drug is FDA approved for trials in Rare Neurological Disease

17/05/2016 - 2 minutes

Newron sees its Investigational New Drug application approved by the FDA. It can now begin clinical trials for Rett Syndrome patients – a rare neurological disorder.

newron_pharmaceuticals_sarizotan_rett_indBased near Milan (Italy), Newron is a Biopharma developing therapies for diseases of the central nervous system (CNS). Last year it raised over €23M to advance its pipeline, which features candidates for Parkinson’s disease and schizophrenia.

Now, Newron has received a positive answer from the FDA for its Investigational New Drug (IND) application regarding sarizotan. This therapy is a novel compound for Rett syndrome, which had already been granted an Orphan Drug Designation.

Sarizotan could become the first drug available to patients of Rett syndrome, a rare neurodevelopmental disorder. The disease is associated with mutations in a gene important to neuron function (MeCP2).

Rett syndrome mainly affects females, and is quite rare – one in 10,000. Besides impaired cognitive and motor development, people affected often suffer from respiratory problems,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member